A Phase 3 interventional study of Nintedanib and Placebo in Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim. Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-20.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing nintedanib in Lung Diseases, Interstitial — 1 open to participants now, 1 under way, 1 of them phase 3. nintedanib · Lung Diseases, Interstitial.
Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is one of 8 in phase 3, and was the 7th registered.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.
Browse Lung Diseases, Interstitial studies →1 of the 11 studies testing nintedanib in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Sites in Poland
Ages 18–74
By country, each count listing its studies:
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2021.
This study's enrollment of 81 is above the median of 60 across 385 interventional studies indexed under Lung Diseases, Interstitial.
Median enrollment 81 across the 11 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 6 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim: 4 open now, 6 under way, 4 of them phase 3. Of 16 finished, 11 (69%) have results posted.
Among the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 11 in phase 3, and was the 10th registered.
Boehringer Ingelheim’s Lung Diseases, Interstitial studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, from their registry updates:
Among Boehringer Ingelheim’s 24 in Lung Diseases, Interstitial:
This tab as a report to print or save as PDF → With an account.
This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old. The purpose of this study is to find out whether a medicine called nintedanib helps people with progressive lung fibrosis.
Participants are put into 2 groups randomly, which means by chance. 1 group gets nintedanib as capsules twice a day. The other group gets placebo as capsules twice a day. Placebo capsules look like nintedanib capsules but do not contain any medicine.
Participants are in the study for about 1 year. During this time, they visit the study site about 10 times. At some visits, participants perform a lung function test. The doctors check whether study treatment can slow down the loss of lung function. The doctors also regularly check participants' health and take note of any unwanted effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with physician diagnosed Interstitial Lung Disease (ILD) who fulfil at least one of the following criteria for Progressive Phenotype within 24 months of screening visit (Visit 1) despite treatment with unapproved medications used in clinical practice to treat ILD, as assessed by the investigator:
Exclusion Criteria:
[Note: Laboratory parameters from Visit 1 have to satisfy the laboratory threshold values as shown above. Visit 2 laboratory results will be available only after randomization. In case at Visit 2 the results do no longer satisfy the entry criteria, the Investigator has to decide whether it is justified that the patient remains on study drug. The justification for decision needs to be documented. Laboratory parameters that are found to be abnormal at Visit 1 are allowed to be re-tested (once) if it is thought to be a measurement error (i.e. there was no abnormal result of this test in the recent history of the patient and there is no related clinical sign) or the result of a temporary and reversible medical condition, once that condition is resolved].
Note: Patients whose Regulatory Authority (RA)/Connective Tissue Disease (CTD) is managed by these medications should not be considered for participation in the current study unless change in RA/CTD medication is medically indicated.
Further exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A soft gelatin capsule of 150 mg Nintedanib was administered orally twice daily (bid) in Chinese patients with chronic fibrosing ILD with progressive phenotype with over 52 weeks. Dose could be reduced to 100 mg bid to manage adverse events.
Drug: Nintedanib
A soft gelatin capsule of placebo matching in size, weight, colour and shape to 150 milligram (mg) or 100 mg soft gelatin capsule of Nintedanib, was administered orally twice daily (bid) in Chinese patients with chronic fibrosing Interstitial Lung Disease (ILD) with progressive phenotype with over 52 weeks.
Drug: Placebo
Soft gelatin capsule
Soft gelatin capsule
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL)
Annual rate of decline in FVC over 52 weeks expressed in milliliter (mL). The main analysis used a restricted maximum likelihood (REML)-based approach with a random slope and intercept model. The analysis included the fixed, categorical effects of treatment, high resolution computed tomography (HRCT) pattern at baseline, fixed continuous effects of time and baseline FVC as well as the treatment-by-time and baseline-by-time interactions. Random effects were included for the patient response for both time and intercept. For patients who prematurely discontinued study treatment, data collected at follow-up visit and visits after treatment discontinuation was included in the analysis.
Time frame: From baseline up to Week 52.
A double blind, randomized, placebo-controlled trial to generate additional data on the efficacy of 150 mg bid nintedanib in Chinese patients with Chronic Fibrosing Interstitial Lung Disease (ILD) with a progressive phenotype compared with placebo over 52 weeks.
| Milestone | Placebo | 150 mg Nintedanib |
|---|---|---|
| Started | 27 | 54 |
| Completed | 20 | 32 |
| Not completed | 7 | 22 |
| Withdrew: Other than listed | 2 | 12 |
| Withdrew: Lack of efficacy | 4 | 0 |
| Withdrew: Adverse event | 1 | 10 |
Annual rate of decline in FVC over 52 weeks expressed in milliliter (mL). The main analysis used a restricted maximum likelihood (REML)-based approach with a random slope and intercept model. The analysis included the fixed, categorical effects of treatment, high resolution computed tomography (HRCT) pattern at baseline, fixed continuous effects of time and baseline FVC as well as the treatment-by-time and baseline-by-time interactions. Random effects were included for the patient response for both time and intercept. For patients who prematurely discontinued study treatment, data collected at follow-up visit and visits after treatment discontinuation was included in the analysis.
| Milliliter/year | Placebo | 150 mg Nintedanib |
|---|---|---|
| Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL) | -191.89 (-313.15 to -70.63) | -85.32 (-176.40 to 5.76) |
Collected over All-cause mortality, serious and other adverse events: From first drug intake until end of trial visit, plus 7 days of residual effect period, up to 53 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 3/27 (11.1%) | 12/27 (44.4%) | 23/27 (85.2%) |
| 150 mg Nintedanib | 6/54 (11.1%) | 20/54 (37%) | 51/54 (94.4%) |
| Event | Placebo | 150 mg Nintedanib |
|---|---|---|
| PneumoniaInfections and infestations | 4/27 | 5/54 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 3/27 | 0/54 |
| Upper respiratory tract infectionInfections and infestations | 2/27 | 0/54 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/27 | 2/54 |
| Cardiac failureCardiac disorders | 1/27 | 1/54 |
| Chest painGeneral disorders | 1/27 | 0/54 |
| COVID-19 pneumoniaInfections and infestations | 1/27 | 2/54 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/27 | 0/54 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/27 | 0/54 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 1/27 | 0/54 |
| Event | Placebo | 150 mg Nintedanib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/27 | 19/54 |
| COVID-19Infections and infestations | 7/27 | 14/54 |
| Hepatic function abnormalHepatobiliary disorders | 2/27 | 12/54 |
| Alanine aminotransferase increasedInvestigations | 1/27 | 10/54 |
| Gamma-glutamyltransferase increasedInvestigations | 1/27 | 10/54 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/27 | 6/54 |
| Aspartate aminotransferase increasedInvestigations | 2/27 | 8/54 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 4/27 | 5/54 |
| Abdominal discomfortGastrointestinal disorders | 1/27 | 7/54 |
| VomitingGastrointestinal disorders | 1/27 | 7/54 |
Treated Set (TS): All patients who were randomized to a treatment group and received at least one dose of study medication.
| Age, Continuous(Years) | Placebo | 150 mg Nintedanib | Total |
|---|---|---|---|
| Mean | 65.8 ± 8.4 | 63.8 ± 8.4 | 64.5 ± 8.4 |
| Sex: Female, Male(Participants) | Placebo | 150 mg Nintedanib | Total |
|---|---|---|---|
| Female | 16 | 28 | 44 |
| Male | 11 | 26 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 150 mg Nintedanib | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 27 | 54 | 81 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 150 mg Nintedanib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 27 | 54 | 81 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Nov 2021 to primary completion in Apr 2024, 29 months.
Results were first posted in May 2025, 1 year after primary completion.
Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's 29 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib